Minimal change disease, membranous nephropathy and focal and segmental glomerulosclerosis (FSGS) are diseases that primarily affect the podocyte. Large gaps of knowledge exist in the pathways of disease pathogenesis. Whereas changes in gene and protein expression in glomerular disorders have been described piecemeal over the past several years, transcriptional regulation of these events is unknown. Several transcriptional factors expressed in the podocyte have been implicated in the pathogenesis of human or experimental disease. Mutations in the zinc finger protein WT1 result in the development of Denys Drash syndrome (1) and Frasier Syndrome (2) . Also, podocyte WT1 expression is dramatically reduced in the collapsing variant of focal sclerosis (3) . Persistent Pax2 expression have also been noted in Denys Drash Syndrome, and may be related to abnormal upstream control by mutant WT1 (4) . Mutations in Lmx1b result in the development of Nail-Patella Syndrome (5, 6) . Knockout of Pod1 results in abnormal development of the mesenchyme and podocytes, resulting in non-functional kidneys (7) . Kreisler acts downstream of Pod1, and mice with mutations in this gene develop proteinuria and effacement of podocyte foot processes (8) . Whereas a direct role of some of these transcriptional factors have been implicated in uncommon clinical situations, transcriptional factors that influence the bulk of changes in gene expression in primary glomerular disorders are unknown.
This paper provides novel insight into the regulation of structurally and functionally important podocyte genes by a relatively new family of transcriptional factors studied for the first time in the podocyte. We describe the cloning, characterization, localization and biological properties of rat Zinc Fingers and Homeoboxes 3 (ZHX3), and discuss its role, along with that of two other family members ZHX1 and ZHX2, in mediating early changes in gene expression during the pathogenesis of glomerular disease. Since proteinuria is a common factor of all primary podocyte disorders, changes in gene expression were studied immediately before and after the onset of proteinuria. The primary goal of these studies is to show how changes in the expression of ZHX family members mediate changes in podocyte gene expression in primary glomerular disease, with a special emphasis on minimal change disease. Whereas some of these changes are also likely to be relevant to the pathogenesis of proteinuria, enquiry into this specific aspect is beyond the scope of this paper. Results from this study indicate that ZHX proteins are major regulators of podocyte gene expression in minimal change disease and focal and segmental glomerulosclerosis. In view of expression of ZHX proteins in multiple organs, involvement of this gene family in the pathogenesis of other disease processes is also very likely.
Experimental procedures
Induction of NTS-induced heterologous phase proteinuria, and extraction of glomerular total RNA: All animal studies were approved by the Animal Care and Use Committee at Northwestern University. Two groups of 100-125 gram Sprague Dawley rats (n=4/group) were injected with 3.5 mg of γ2-nephrotoxic serum or normal Sheep IgG intravenously via the tail vein, as previously described (12), urinary protein excretion over the next 18 hours measured, and both groups euthanized 24 hours after injection. Following euthanasia, small sections of kidney from each group were retained for histological studies, whereas the rest of the kidneys were pooled to extract glomeruli by sieving at 4 0 C under aseptic conditions. After confirming the purity of the extracted glomeruli by light microscopy, onefifth of the extracted glomeruli were frozen at -80 0 C in the presence of protease inhibitors for future protein studies, whereas the rest of the glomeruli were used immediately for extraction of total RNA using TRIzol reagent (Invitrogen, Carlsbad CA). The total RNA extracted from different groups was quantified simultaneously as mentioned above. Some of the total RNA was used for suppression subtractive hybridization as described below. Of the rest, cDNA templates for Real Time PCR were generated by reverse transcription with Superscript III (Invitrogen), using 2 µg total RNA per template and three identical thermocyclers on the same day. RNase H was added to each template at the end of reverse transcription. Templates were stored at -20 0 C prior to conducting real time PCR studies.
Suppression subtractive hybridization-PCR:
Total RNA from the NTS and control group glomeruli was used to generate cDNA using the Super SMART PCR cDNA Synthesis Kit (Clontech, Mountain View CA), which were then subjected to suppression subtractive hybridization using the PCR-Select cDNA Subtraction Kit (Clontech) The PCR amplified differentially expressed products were resolved on a 1% agarose gel, visible bands excised, DNA extracted, cloned into pCRII and sequenced in sense and antisense directions. The sequences were subjected to a BLAST search to identify the genes. One of the then unknown genes identified was clone 1102. Taqman probes were developed to each fragment as described below, and the extent of differential gene expression quantified by real time PCR.
Cloning of full length rat ZHX3: Clone 1102 containing a 1643 bp differentially expressed gene fragment was used to screen a Uni-ZAP XR rat kidney cDNA library (catalog # 937517, Stratgene, La Jolla CA). Approximately one million clones of a rat kidney cDNA library were screened with clone 1102, resulted in the identification of five overlapping clones encoding for a 2863 bp fragment that extended the 3' end of the sequence up to the polyA tail ( Figure 1 ). With the subsequent availability of the human ZHX3 sequence (gi 28866856), the 5' end of the gene was identified by homology search. The full length gene was sequenced (Genbank accession number rat ZHX3 DQ017884) and cloned into pCRII, and full length eukaryotic expression constructs developed in pcDNA3.1/V5-His-A.
Since several experiments were planned in cultured mouse GECs, mouse ZHX3 was also cloned into pcDNA3.1/V5-HisB (Genbank accession number DQ317973) using primers based on existing Genbank sequences.
For Northern blot analysis, rat kidney mRNA was purified from total RNA using the Oligotex mRNA maxi kit (Qiagen, Valencia CA). The insert of clone 1102 excised from pCRII to generate a probe labeled with 32 PdCTP (MP biomedical, Irvine CA) using the Rediprime II random primer labeling system (GE healthcare, Piscataway NJ). Northern blots were performed under high stringency conditions.
Generation of anti-ZHX3 antibody: using primers K335 (gcgc ggatcc aagaccatggtgctgccgggtgcca)and K336 (gcgc ctcgag aagggccttggatgtgggcagggg), a part of rat ZHX3 encoding for amino acids 16 to 290 (including the zinc finger domains region) was cloned into pGEX-6P-1 between the BamHI and XhoI sites and expressed in E. Coli using standard protocols. The recombinant His tagged protein was purified over nickel columns and used to immunize rabbits to generate a polyclonal rabbit anti-rat ZHX3 antibody, which was tested for reactivity by ELISA, Western blot and immunofluorescence.
The following primary antibodies were purchased from commercial sources: mouse anti-ZHX2 (Abnova, Taiwan), rabbit anti-ZHX1 (Bethyl laboratories Montgomery TX), mouse anti-V5 (Invitrogen), goat anti-V5 (Abcam Cambridge MA), mouse anti-FLAG (Stratagene), mouse anti-HSV (Novagen, San Diego CA), mouse anti-actin (Sigma, St Louis MO) and rabbit anti-histone B4 (Bethyl laboratories).
Cloning of rat Cathepsin L, Cathepsin B and Flavin Containing Monooxygenase 1 promoter regions into pSEAP: A previously published clone for the Cathepsin L promoter (13) was used. The 3198 bp insert contained the promoter region, exon1, intron1 and part of exon 2. The start codon was noted to be present in exon 2.
Since there is an alternative start site in the Cathepsin L gene, two studies to verify the transcriptional start site in glomerular RNA were first conducted. Primer Extension Analysis was done using total RNA from rat glomeruli, and reverse primers based in exon 1 (K453--gatccccggaggtcgccgaggtccgag) and exon 2 (K454--cagaggacagccaggaggagtaaagggg) using the AMV reverse transcriptase primer extension system (Promega). 5 For footprinting studies, these plasmids were cut with Hind III, labeled with [γ-32 P] ATP using T4 Polynucleotide kinase, a single-endlabeled probe generated by further digesting the 3' end with Xho I, purified by phenol: chloroform: isoamyl alcohol (25:24:1) and precipitated with ethanol. The DNA-protein binding reaction mixture (50 µl) contained labeled DNA probe, 2 µg of protein extract purified (prepared as described above), 25 mM Tris-HCl (pH 8.0), 50 mM KCl, 6.125 mM MgCl 2 , 0.5 mM EDTA, 10% glycerol, and 1 mM dithiothreitol. After incubation for 10 min on ice, 50 µl of 10 mM MgCl 2 and 5 mM CaCl 2 were added followed by the addition of 0.2 U of DNase I and incubation was continued at room temperature for 2 min. DNase I digestion was quenched by the addition of 90 µl of stop solution (200 mM NaCl, 30 mM EDTA, 1% SDS), and the DNA template was purified by phenol-chloroform (1:1) extraction and ethanol precipitation. The DNA samples were dissolved in 8 µl of formamide-loading dye and heating to 90°C for 2 min. The samples were then loaded onto a denaturing 6% polyacrylamide-7M urea sequencing gels. A 25-bp DNA stepladder labeled (using polynucleotide kinase) with [ -32 P] ATP was as a size marker.
For electrophoretic mobility shift assay (EMSA), consensus sequences of the CdxA binding motif (A/C)TTTAT(A/G), as suggested by DNA footprinting studies, and several other putative transcriptional factor binding sites (SRY, MZF1, NF-AT, GATA-2, AML-1a, AP-4) between -980 and -800 were used. Complementary oligonucleotides in equimolar amounts were hybridized for 5 min at 95 °C and then were allowed to cool to room temperature. The double stranded oligonucleotide probe was labeled with [ -32 P] ATP and T4 polynucleotide kinase in 20 µl of binding buffer (10 mM Tris, pH 7.5, 0.5 mM EDTA, 0.5 mM dithiothreitol, 4% glycerol, 1mM MgCI2, NCI 50mM, 0.05mg/ml poly (dI-dC).poly (dI.dC) ) for 10 minutes at room temperature. One µl of 32-P labeled CdxA, or other binding site, consensus double stranded oligonucleotide were added to 2 µg recombinant ZHX3 protein and incubated for another 20 minutes at room temperature. In CdxA competition studies, 100-fold excess of cold consensus or cold mutant CdxA double stranded oligonucleotide, as appropriate, were added to the reactions. For supershift assays, recombinant ZHX3 was incubated at room temperature with rabbit anti-rat Zhx3 antibody for 30 minutes before labeled CdxA probe was added, separated on a 6% DNA retardation polyacrylamide gel in 0.5x TBE, dried, and developed by autoradiography.
Sense strand sequences for wild type and mutant CdxA used in EMSA studies were as follows: Wild type ATTTTT ATTTATA TGAGTGC; mutation#1 ATTTTT AATTATA TGAGTGC; mutation # 2 ATTTTT ATATATA TGAGTGC; mutation # 3 ATTTTT ATTAATA TGAGTGC; mutation # 4 ATTTTT ATTTTTA TGAGTGC; mutation # 5 ATTTTT ATTTAAA TGAGTGC.
Induction of other rat models of proteinuria: Since the NTS model does not represent a specific form of human glomerular disease, the expression of ZHX3 around the onset of proteinuria was studied in puromycin aminonucleoside nephrosis (PAN, a model of minimal change disease), and passive Heymann nephritis (PHN, a model of membranous nephropathy). In each model, tissue was preserved after euthanasia to confirm the induction of glomerular injury by light microscopy, immunofluorescence microscopy and conventional electron microscopy. Isolated glomeruli were used for extracting protein or for generation of 12-24 cDNA templates for real time PCR.
Special emphasis was placed on the quality of total RNA. In the initial studies, total RNA was quantified and its quality assessed by OD260 and agarose gel electrophoresis, respectively. RNA with OD 260 < 2.0 was further purified by phenol chloroform extraction. In later experiments, the Agilent 2100 bioanalyzer was used to assess total RNA quality and quantity. Glomerular proteins were extracted using SDS-PAGE sample buffer without bromophenol blue and quantified as previously described (14) . Equal amounts of protein were added to each lane in quantitative Western blots, and additional loading controls were done using anti-actin antibodies after stripping the membrane.
Induction of PAN:
15 mg / 100 gm of puromycin aminonucleoside (Sigma, St. Louis MO) or an equivalent volume of sterile filtered PBS were injected intravenously into different groups of 75-100 gram male Wistar rats (n = 4 rats/group, baseline proteinuria < 1 mg/ 18 hours), and rats euthanized on Days 3, 6 and 10 after injection. Rats develop proteinuria on Day 4 to Day 5. Prior to euthanasia, 18-hour urine collection was obtain in metabolic cages and proteinuria assessed.
Induction of PHN:
Male Wistar rats (n = 4 rats/group, rats weigh 75-100 grams) were injected with 0.75 ml and 0.5 ml of sheep antirat Fx1a or control sheep serum (Sigma, St Louis MO) on two consecutive days, and proteinuria measured on Days 3, 6 and 10 after the first injection. Rats typically become proteinuric on Day 4 or Day 5. Different groups of rats were euthanized on Days 3, 6 and 10, kidneys removed and processed as for the PAN group.
Transfection of ZHX expression constructs and SiRNA into cultured cells: HEK 293 cells and mouse glomerular epithelial cells (GECs) were cultured as previously described (12) . Rat ZHX3 cDNA sequence (bp 1-2847) was cloned into pcDNA 3.1/V5-His A using primers K534 (5'-gcgc gaattc tg gccacc atggccagcaagaggaagtcc-3') and K536 (5'-gcgc ctcgag ctg ttcgagctgacgtccgg-3') between the EcoRI and XhoI sites. Baseline expression of ZHX3 in these cells was first assessed by staining with anti-ZHX3 antibody. Then, expression of recombinant rat ZHX3 was assessed in HEK293 cells by staining with mouse anti-V5 antibody. Nuclei and the actin cytoskeleton were stained using TOPRO3 iodide and FITC-phalloidin, respectively.
Mouse ZHX1 was cloned into TOPOpcDNA3.1 (Invitrogen) using primers K795 (5'-gccaccatggcaagcagacgaaaatcaacaacacct-3') and K796 (5'-gtcatccgatttagaaagcttccgcttca-3'), and into pIRES-hrGFP-1a (Stratagene) using primers K728 (5'-cccggcatgcgccaccatggcaagcagacgaaaatcaacaac acc-3') K740 (5'-gcccctcgagtcagtcatccgatttagaaagcttccgcttcacat gtcgtggg-3'). Mouse ZHX2 was cloned into pTriEx-3 Neo (Novagen) using primers K730 (5'-cgcgggatccgccaccatggcaagcaaacggaaatctacaac -3') and K739 (5'-gcgcagatctctgcaggggtgctgtcggagtcgg-3').
Recombinant His-and V5-tagged rat ZHX3 was purified from transfected HEK293 cells after lysis using the Probond Purification System (Invitrogen Regulation of mouse ZHX3 promoter activity and gene by recombinant mouse ZHX3: Since in vitro studies on the effect of changes in ZHX3 expression on target genes were planned in mouse GECs, full length mouse ZHX3 cDNA was cloned into pCDNA 3.1 V5-His B between the BamHI and XhoI sites using primers K691 (5'-gcgc ggatcc gccacc atggccagcaaaaggaagtccacc-3') and K692 (5'-gcgc ctcgag cg gtctgcttcgagttgacgtccag-3') designed from the published sequence. A 1.5 Kb fragment of mouse genomic DNA upstream of exon 1 of mouse ZHX3 predicted to have promoter activity using Neural Network Promoter Prediction program (http://www.fruitfly.org/seq_tools/promoter.ht ml) was cloned into pSEAP2-basic (Promega), and used for co-transfection studies in HEK293 cells with mouse ZHX3-pcDNA or control constructs.
Development of Taqman probes for Real
Time PCR: (Supplemental Tables 3 and 4) Real time PCR primers and probes (FAM-MGB combination) were designed for each gene of interest using Primer Express 2.0 software (Applied Biosystems, Foster City CA) as previously described (14) .
Real time PCR was performed in 96 well format on the ABI Prism 7000 (Applied Biosystems) in multiplex mode (i.e. study primers / probe + 18S control primers / probe). In each experiment, all genes were initially screened with 3-4 templates/group, and if found to be differentially expressed, confirmed by another 6 templates/group.
Selection of candidate genes for studying the gene expression profile of puromycin nephrosis by real time PCR:
Candidate genes met two or more of the following criteria: 1) they are critical for maintaining the structure and function of the glomerular capillary loop, 2) within the glomerulus, they are relatively specific to the glomerular capillary loop, and 3) they have been associated with, or have a possibility of being associated with proteinuria.
Establishment of cutoff of significance for in vivo studies:
Pilot studies were conducted in various animal models to define a cutoff in gene expression that would lead to concomitant significant changes in protein expression by Western blot. The system was specifically designed to assess changes in rat glomerular mRNA expression using 18S as a control. Mean changes in mRNA expression of 2, 2.5, 3, 3.5 and 4 fold were studied. Consistent changes in protein expression were noted at mean changes of 3-fold and above using 18S probes for normalization. Therefore, a mean change in mRNA expression in excess of three fold was considered significant. Assuming that 25% to 33% of total RNA from glomeruli comes from a single cell type e.g. podocyte or endothelial cell, this roughly translates to a 9-12 fold change in expression of a cell type specific gene e.g nephrin for podocytes and TIE2 for endothelial cells. Translation of the open reading frame of rat ZHX3 revealed a 951 amino acid sequence (predicted size 105 kDa) including five HOXlike homeobox domains and two zinc finger C2H2 domains, similar to its human counterpart (9) . Rat ZHX3 protein has approximately 85% and 94% homology with its human and mouse counterparts, respectively. Western blots of rat glomerular protein extracts revealed prominent bands at 105 kDa and 80 kDa on 7.5% SDS PAGE. The 80 kDa band is most likely a posttranslational C-terminal cleavage product of the full length protein (105 kDa band), since it can be reproduced as a C-terminal V5-tagged band following transfection of full length ZHX3 into HEK 293 cells, that is also reactive with the anti-ZHX3 antibody. A previous study (9) identified two nuclear localization signals in human ZHX3. By transfecting various GFP-labeled partial constructs into HEK 293 cells, these investigators were able to demonstrate nuclear localization of two distinct recombinant ZHX3 fragments. Based on homology with human ZHX3, two nuclear localization signals for rat ZHX3 are predicted between amino acids 1-107 and 490-548. Conventional immunofluorescence staining of normal rat kidney sections revealed colocalization with CD2AP, indicating expression in the podocyte (Figure 2 ). Very little overlap was noted with podocyte nuclear marker WT1.
ZHX3 expression in normal and diseased podocytes.
Confocal imaging revealed prominent non-nuclear localization, including peripheral and perinuclear staining, in podocytes, with only approximately 5 -10% staining in the podocyte nucleus (Figure 3 , panels A, B, E, F). Additional nuclear and non-nuclear expression is noted in selected tubular segments. To test if ZHX3 transcriptional factor activity could be linked to changes in gene expression during the early phases of the pathogenesis of glomerular disease, its expression in the pre-proteinuric (Day 3) and the early proteinuric phase (Day 6) of PAN and PHN were studied (Figures 3  and 4) . The normal peripheral capillary loop pattern disintegrates into a coarse punctuate pattern in the PAN Day 6 kidney, and a substantial amount of peripheral ZHX3 was noted to have redistributed into the podocyte nucleus in multiple kidney sections (Figure 3 ). Transient downregulation of ZHX3 mRNA expression prior to the onset of proteinuria (Day 3 ↓ 3.27 + 0.23; cutoff for significant change is 3), followed by partial recovery thereafter (Day 6 ↓ 2.94 + 0.16) were noted in PAN, but not in PHN at the same time points (Figure 4 ). Concomitant changes in glomerular ZHX3 protein reduction were noted by Western blot. Densitometry analysis of these bands revealed changes on day 3 and day 6 to be significantly different from control (P ranging from < 0.05 to < 0.001). ZHX3 expression was also studied in human kidney biopsies from four patients with minimal change disease and corresponding age and sex matched control biopsies from transplant donors ( Figure 5 ). In the controls, as in rats, glomerular ZHX3 has a capillary loop pattern, with occasional spotty expression in podocyte nuclei. Overall, approximately 10% ZXH3 appeared to be nuclear. In patients with minimal change disease, overall glomerular ZHX3 expression was reduced, the linear capillary loop pattern replaced by a coarse speckled pattern, and at least 50% of podocyte nuclei (compared to an occasional podocyte nucleus at baseline) had a diffuse ZHX3 stain in podocyte nuclei.
DNA binding properties of ZHX3.
In order to define the biological role of ZHX3, its potential transcriptional factor activity was studied. Co-transfection of Cathepsin L-A and Cathepsin B with rat ZHX3-pcDNA ( Figure 6 , panels A, B) caused repression of SEAP activity with both constructs (P < 0.001). No significant effect was noted with flavin containing monooxygenase 1 (P > 0.05) ( Figure 6, panel C) . In addition, overexpression of both rat and mouse ZHX3 in mouse GECs causes significant downregulation of mouse Cathepsin L expression by real time PCR. The cathepsin L promoter was then used as a model to identify a putative ZHX3 DNA binding site. Deletion constructs of the Cathepsin L promoter suggested that Construct B, but not construct C, possessed minimum promoter activity ( Figure 6, panel D) . Parts of sub-construct E (part of B) ( Figure 6, panel F, G) containing a CdxA binding motif appeared to be protected in foot printing studies. Electrophoretic mobility shift assay (EMSA) and supershift studies confirmed binding of ZHX3 to recombinant CdxA ( Figure 6, panel H) . We also studied potential autoregulation of ZHX3 gene expression by ZHX3 protein. Cotransfection of mouse ZHX3 with promoterreporter constructs made from a 1.5 Kb segment of mouse ZHX3 genomic DNA upstream of the mouse ZHX3 ATG showed repression of promoter activity. Also, overexpression of V5-tagged rat ZHX3 in mouse GECs caused severe downregulation of mouse ZHX3 expression, as assessed by a Taqman probe highly specific for mouse ZHX3 ( Figure 6, panel I) . Both results indicate a negative feedback of ZHX3 protein on its own gene expression.
Effects of altered ZHX3 mRNA expression in vitro on podocyte gene expression.
A series of in vivo and in vitro studies was undertaken to assess the specific effects of ZHX3 in modulating podocyte gene expression in glomerular disease. Overexpression of ZHX3-V5 constructs causes predominant nuclear localization of the recombinant protein ( Figure  2 , panels G, H; Figure 7 , panel E). Mild knockdown of ZHX3 in cultured GECs at 24 hours, followed by recovery of ZHX3 expression at 48 and 72 hours, mimicked the transient downregulation followed by recovery in PAN, and was associated with increased nuclear ZHX3 expression in the recovery phase (Figure 7 , panels A to D, panel M). Severe knockdown not associated with recovery for up to 72 hours was associated with a persistent reduction of total cellular ZHX3 protein (Figure 7, panel N) . Gene expression profile of a panel of glomerular capillary loop genes was studied in glomeruli of rats with PAN by real time PCR (Table 1) . Similar time course studies were conducted following transient knockdown, sustained knockdown and overexpression in cultured GECs of the corresponding podocyte genes. The genes differentially expressed during PAN were qualitatively identical to the transient knockdown study, thereby indicating that change in the expression of ZHX3 alone can account for the gene expression profile in PAN. Severe ZHX3 knockdown largely affected a different set of genes in our panel, though some of the transient knockdown study genes were paradoxically upregulated. Interestingly, ZHX3 overexpression studies in GECs show that not all the genes in either knockdown study appear to be regulated directly by ZHX3 ( Table 2 ). The genes studied in vivo and in vitro by Taqman real time PCR are listed in Supplemental Tables 3  and 4 .
Role of ZHX1 and ZHX2 in podocyte disease. ZHX proteins are expressed in multiple organs of the body (9, 10). Since ZHX1 and ZHX2, the two other known members of the family, form heterodimers with ZHX3 (9, 10), we demonstrated expression of both proteins in podocytes in vivo ( Figure 8 ) and in cultured GECs. Whereas ZHX3 and ZHX1 are also expressed in selected tubular segments, the expression of ZHX2 in the kidney is glomerular-and podocyte-specific (data not shown). Also, of the three ZHX proteins, ZHX1 has more nuclear expression in podocyte in vivo (about 20%) compared to ZHX2 and ZHX3 (about 5-10%). The gene expression profile of in vivo podocyte genes was studied in cultured GECs following overexpression of ZHX1, ZHX2 and ZHX3 (Table 2 ). Most genes in our panel were regulated by one or more members of the ZHX family. Only 30% of the genes were regulated by two ZHX proteins, of which only one gene was regulated by all three. ZHX3 does not influence ZHX1 or ZHX2 gene expression, and vice versa, in the overexpression studies. In a separate study, mRNA expression of ZHX1 and ZHX2 appear to be unchanged in PAN.
ZHX heterodimers form the basis of the predominant non-nuclear localization of ZHX proteins in the normal podocyte. All ZHX proteins have two nuclear localization signals (9, 10) . In vitro, nuclear entry of ZHX3 can be achieved by transient overexpression, or during recovery following transient knockdown. Since ZHX3 forms heterodimers with ZHX1 and ZHX2, we hypothesized that baseline ZHX3 expression is localized predominantly to the non-nuclear compartment as a heterodimer, whereas monomeric or homodimeric ZHX3, as generated following ZHX3 overexpression and transient knockdown, migrates readily into the nucleus. Co-expression of recombinant ZHX3-V5 and ZHX2-HSV caused substantial pooling of the recombinant protein in the non-nuclear compartment, whereas overexpression alone caused near exclusive nuclear localization ( Figure 7 , panels E to L). We then studied the redistribution of ZHX proteins (ZHX1 data shown as an example) following SiRNAmediated knockdown of a one or two family members ( Figure 9 ). Four-fold knockdown of ZHX3 mRNA in GECs induced increased nuclear expression of ZHX1 at 48 hours. ZHX1 nuclear expression was even more prominent when both ZHX3 and ZHX2 were simultaneously knocked down four-fold each. Therefore, knockdown of ZHX3 or ZHX2 alone or in combination, frees increased amounts of non-heterodimeric ZHX1 to migrate into the nucleus.
Discussion
In addition to the cloning and characterization rat ZHX3 , and an in-depth study of its DNA binding properties, this paper also brings out features of the ZHX family that are critical in understanding their function. These include autoregulation of ZHX gene promoters by the corresponding ZHX protein, the absence of cross-regulation of promoter activity among family members, regulation of nuclear entry by formation or loss of heterodimers, and the concept that presence or absence of a recovery phase of expression following downregulation of single family member (ZHX3) can govern whether the podocyte develops gene expression changes of minimal change disease or focal sclerosis, respectively.
Most changes in gene expression in GECs following mild, transient knockdown and severe, persistent knockdown of ZHX3 are readily explained as direct effects of ZHX proteins. Downregulation of COL4A3, COL4A4, angiopoietin 2 and vascular endothelial growth factor (VEGF) during the recovery phase is explained by nuclear entry of newly synthesized ZHX3 protein, whereas podocalyxin and β1 integrin downregulation are likely related to nuclear entry of small amounts of free ZHX2 during the mild ZHX3 knockdown. During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration and aminopeptidase A due to ZHX1 or ZHX2, or both. Transient upregulation of COL4A3 and COL4A4 may be due to a loss of ZHX3 effect, indicating that ZHX3 potentially binds to their bidirectional promoter at baseline. However, some specific gene changes are not readily explained by direct ZHX interaction. Of these, transient upregulation of podocalyxin may be a complex combination effect of ZHX2 and WT1 downregulation, and may have been contributed to by other genes not studied by us. Similarly, downregulation of P cadherin and perlecan may be related to dose dependent effects of ZHX proteins, or due to effects of other proteins regulated by ZHX proteins.
Of the genes downregulated by severe knockdown, WT1 provides a direct link with focal sclerosis and podocyte dedifferentiation. Very little is known about factors that regulate the expression of WT1 in the podocyte. WT1 expression is reduced or completely lost in certain forms of FSGS. Based on our studies, increased availability of free ZHX2 following severe downregulation of ZHX3 in FSGS would most likely explain downregulation of WT1 in FSGS. Therefore, the extent of downregulation of ZHX3 may determine whether a patient develops MCD or FSGS. This may also correlate with the observation that whereas a single injection of puromycin aminonucleoside produces a minimal change disease like picture, repeated injections of the same cause FSGS (11) . The repeated injections could potentially convert the transient downregulation followed by recovery profile of ZHX3 into persistent downregulation, that results in downregulation of WT1 and development of FSGS. Also, the downregulation of Lmx1b in the ZHX2 overexpression and the ZHX3 severe knockdown studies adds a new dimension to the regulation by ZHX2 via Lmx1b of several podocyte and matrix genes (15, 16, 17) .
Several properties of ZHX proteins allow for a key role in mediating changes in gene expression during the development of glomerular disease. First, whereas some nuclear presence regulates the expression of selected genes at baseline, predominant localization in the non-nuclear compartment allows for the majority of ZHX proteins to be transcriptionally inactive in the normal in vivo podocyte. Next, interaction of ZHX proteins among themselves, and the absence of crossregulation of their genes by the individual proteins, allows for free ZHX proteins to regulate their target genes when a binding partner is selectively downregulated. The ability of these proteins to bind specific promoters is likely to be influenced by multiple factors other than DNA binding motif (e.g. CdxA for ZHX3). One such factor may be nuclear concentration of the specific ZHX protein. Therefore, overexpression of a ZHX protein, which causes a much larger amount of protein to enter the nucleus than knockdown of its binding partner, may cause the same protein to bind promoters in a heterogeneous manner. Third, the presence of two nuclear localization signals (9, 10) , one each in the zinc finger and homeobox regions, may facilitate nuclear entry of the intact protein, as well as individual fragments, which is possible at the very least for ZHX3. Equally interesting would be the further investigation of the downstream effects of ZHX2 on WT1 expression in FSGS.
Finally, since ZHX proteins are expressed in multiple organs in the body, it is quite likely that similar changes in ZHX gene and protein occur elsewhere in the body during development of disease. Thus, the mechanisms described in this paper are like to have relevance beyond glomerular disease.
Reiser (Massachusetts General Hospital) for mouse GECs. We also express our gratitude to Lawrence Holzman (University of Michigan at Ann Arbor) for reading early versions of this manuscript and giving useful suggestions. D to H) . The minimum promoter activity region was localized between -361 and -1176 (D) and divided into four overlapping fragments (E) used for DNase I footprinting. Fragment E showed protection with both nuclear extract from ZHX3-pcDNA transfected HEK293 cells and His-tag purified ZHX3 from the same cells in the same region (F). Transcriptional factor motifs in this region (boxed in G) and the surrounding fragment were mapped, and used for EMSA. As predicted by footprinting using nuclear extract from ZHX3-pcDNA transfected HEK293 cells, only the CdxA motif bound with ZHX3. The CdxA motif -ZHX3 binding (H, lane 2) was entirely abolished by a 100-fold excess of wild type cold Cdxa motif (H, lane 8), but not by five cold mutant CdxA motifs (H, lanes 3 to 7). Supershift of this complex using anti-ZHX3 antibody (H, lane 9) was dramatically reduced by competition with wild type CdxA motif (H, lane 10). Transfection of rat ZHX3-pcDNA construct (study group, red) or empty vector (control group, blue) into mouse GECs resulted in 68-fold reduction in intrinsic mouse ZHX3 mRNA expression after 24 hours, as assessed by real time PCR (I) using a highly specific mouse probe, indicating that ZHX3 is a repressor of its own promoter (n = 3 readings/ group). ZHX1 and ZHX2 are expressed in the podocyte, since they co-localize with CD2AP. Small amounts of both proteins are also present in selected, presumably podocyte, nuclei (arrows in merged panels D and H). Of the three ZHX protein, ZHX1 has the maximum baseline podocyte nuclear expression (approximately 20%). Magnification 400x. Figure 9 : Effect of changes in ZHX family gene expression on ZHX protein distribution in cultured GECs. Results of two separate experiments are shown. Panels a to i are confocal images (magnification 630x) from the first experiment using SiRNA -mediated knockdown to assess the effect of control knockdown (A to C), four-fold ZHX3 knockdown (D to F), and four-fold knockdown each of ZHX3 and ZHX2 (G to I) on nuclear expression of ZHX1 (red) after 48 hours knockdown. Significant increase in nuclear ZHX1 expression is noted in merged images F and I, compared to control C (I > F). Nuclear stain is Sytox green. Panel J is a Western blot from the second experiment to study this compartment shift of ZHX1 following four-fold knockdown of both ZHX2 and ZHX3. Nuclear extracts after 48 hours reveal enrichment of ZHX1 (similar to panels H and I), whereas corresponding cytosolic extracts reveal depletion of ZHX1 from this compartment. Magnification 630x none pcDNA ZHX3 ZHX3
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